HER2 Biomarkers News and reporting on HER2 biomarkers. Jan 20, 2023 FDA Approves Seagen's Tukysa, Genentech's Herceptin for HER2-Positive Colorectal Cancer Patients Jan 19, 2023 Gene Signature Beats TILs as Biomarker of Response to Anti-HER2 Therapy Premium Jan 6, 2023 Immune Signatures Outperform TILs for HER2-Positive Breast Cancer Prognoses Jan 4, 2023 Precision Oncology in 2022: New Drugs and Tests Amid Ongoing Access Barriers Premium Dec 21, 2022 Jazz Takes Up Option on Zymeworks' HER2-Targeted Bispecific Antibody Dec 20, 2022 NICE Backs Enhertu via Managed Access Program for Certain HER2-Positive Breast Cancer Patients Dec 19, 2022 Carrick Therapeutics, Menarini Group Studying Samuraciclib With Elacestrant Dec 10, 2022 Regeneron's Dual Immunotherapy Cocktail Shows Promise as Neoadjuvant Breast Cancer Option Premium Dec 8, 2022 Circulating Tumor Cell-Guided Treatment Improves Outcomes for Some Breast Cancer Patients Premium Dec 8, 2022 Adding Ibrance to Fulvestrant Doesn't Benefit CDK4/6 Inhibitor-Refractory Breast Cancer Patients Premium Dec 8, 2022 New HER2-Low Category Spurring Efforts to Understand Breast Cancer Biology, Develop Better Tests Premium Dec 7, 2022 SABCS Data Solidifies Enhertu as Preferred Second-, Third-Line HER2-Positive Breast Cancer Treatment Premium Dec 7, 2022 Enhertu Shows Activity in Early-Stage HER2-Low Breast Cancer Patients in Study Reported at SABCS Dec 7, 2022 Kisqali Outperforms Combination Chemo in Aggressive HR-Positive, HER2-Negative Breast Cancer Premium Dec 1, 2022 Carrick Therapeutics Receives $35M Investment From Pfizer; Raises $25M in Series C Funding Round Nov 28, 2022 NICE Recommends BMS's Opdivo Plus Chemo for HER2-Negative, PD-L1-Positive Gastric Cancer Nov 23, 2022 Higher TIL Levels in Residual Disease May Predict Worse Survival in HER2-Positive Breast Cancer Premium Nov 8, 2022 Ono Pharmaceutical Exercises Option to Jointly Develop CAR T-Cell Therapy With Fate Therapeutics Oct 25, 2022 Pluvicto Sales Ramp up, Kisqali Gains Continue in Q3 for Novartis Premium Oct 20, 2022 GE Healthcare Educating Docs on Guidelines-Backed Use of Imaging Agent for ER-Positive Breast Cancer Premium Load More Breaking News Ratio Therapeutics Raises $20M in Series A Financing Guardant Health, AnHeart Tx to Develop Blood- and Tissue-Based CDx for NSCLC Drug Ellipses Pharma Cleared by FDA to Open Phase I/II AML Trial Survey Reveals Changing Genetic Testing Patterns, Persistent Disparities in Precision Oncology Amgen's Lumakras Sales Increased 58 Percent in Q4 2022 Coeptis Therapeutics, University of Pittsburgh Studying SNAP-CAR Therapy in HER2-Positive Cancers
